Without 1α-hydroxylation, the gene expression profile of 25(OH)D₃ treatment overlaps deeply with that of 1,25(OH)₂D₃ in prostate cancer cells.

ABSTRACT: Recently, the antiproliferative action of 1,25(OH)₂D₃ (1,25D3), an active metabolite of vitamin D₃, in the management of prostate cancer has been argued rigorously. In this study, we found that at a physiological concentration, 25(OH)D₃ (25D3), the precursor of 1,25D3 and an inactive form of vitamin D because of its much weaker binding activity to the vitamin D receptor (VDR) compared with 1,25D3, had a gene expression profile similar to that of 1,25D3 in prostate cancer LNCaP cells. By immunocytochemistry, western blotting, and CYP27B1 and/or VDR knockdown by small interfering RNAs, we found that 10^-7 M 25D3, which is within its uppermost physiological concentration in the bloodstream, induced VDR nuclear import and robustly activated

SUBMITTER: Susa T 

PROVIDER: S-EPMC5998076 | biostudies-literature | 2018 Jun

REPOSITORIES: biostudies-literature